Drug Profile
PF 610355
Alternative Names: PF-00610355; PF-610,355Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antiasthmatics; Benzeneacetamides; Sulfonamides
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 11 Aug 2011 Discontinued - Phase-I for Asthma in Belgium (Inhalation)
- 11 Aug 2011 Discontinued - Phase-II for Asthma in Germany (Inhalation)
- 11 Aug 2011 Discontinued - Phase-II for Asthma in Sweden (Inhalation)